Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01959594 · ClinicalTrials.gov registry record · Phase 1

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT01959594: Completed Phase 1 study, sponsored by Pfizer.

NCT01959594 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01959594, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

This study is designed to evaluate the safety and plasma concentrations of PF-06412562 in healthy volunteers following three times daily oral dosing of PF-06412562 for 14 days

Interventions

  • DRUG 3 mg PF-06412562
  • DRUG 10 mg PF-06412562
  • DRUG 25 mg PF-06412562
  • DRUG PF-06412562 TBD mg

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2013-11
Est. Completion 2014-03
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT01959594 record still lists

NCT01959594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 4 interventions - of which 3 mg PF-06412562 is the first listed.

NCT01959594 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01959594 about?

NCT01959594 is a clinical study titled "A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers". This study is designed to evaluate the safety and plasma concentrations of PF-06412562 in healthy volunteers following three times daily oral dosing of PF-06412562 for 14 days

What is the current status of trial NCT01959594?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-11. Estimated completion is 2014-03.

What interventions are being tested in trial NCT01959594?

The interventions under investigation include: 3 mg PF-06412562 (DRUG), 10 mg PF-06412562 (DRUG), 25 mg PF-06412562 (DRUG), PF-06412562 TBD mg (DRUG).

Who is sponsoring clinical trial NCT01959594?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01959594's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01959594, the US trial registry maintained by the National Library of Medicine. NCT01959594 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.